Baker Julian's Form 4 filing
Kodiak Sciences Inc.KOD ยท filed Jan 31, 2022
- Accession no.
- 0001209191-22-005629
- Filed
- Jan 31, 2022, 5:06 PM ET
- Trade date
- Jan 27-31, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 12 non-derivative transactions. Open-market purchases total $18.1M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Baker JulianCIK 0001087939 | Director, 10% Owner |
| Baker FelixCIK 0001087940 | Director, 10% Owner |
| Baker Bros. Advisors LPCIK 0001263508 | Director, 10% Owner |
| Baker Brothers Life Sciences LPCIK 0001363364 | Director, 10% Owner |
| 667, L.P.CIK 0001551139 | Director, 10% Owner |
| Baker Bros. Advisors (GP) LLCCIK 0001580575 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 27, 2022 | Common Stock | PPurchaseAcquired | +86,479 | $52.04F1 | +$4,500,496.88 | 14,114,316 | Indirect | |
| Jan 27, 2022 | Common Stock | PPurchaseAcquired | +117,291 | $51.59F5 | +$6,050,819.84 | 14,231,607 | Indirect | |
| Jan 27, 2022 | Common Stock | PPurchaseAcquired | +4,465 | $51.67F6 | +$230,712.35 | 1,159,043 | Indirect | |
| Jan 27, 2022 | Common Stock | PPurchaseAcquired | +54,024 | $51.67F6 | +$2,791,490.31 | 14,285,631 | Indirect | |
| Jan 28, 2022 | Common Stock | PPurchaseAcquired | +1,851 | $49.70F8 | +$91,996.74 | 1,160,894 | Indirect | |
| Jan 28, 2022 | Common Stock | PPurchaseAcquired | +22,395 | $49.70F8 | +$1,113,056.13 | 14,308,026 | Indirect | |
| Jan 28, 2022 | Common Stock | PPurchaseAcquired | +1,414 | $50.56F9 | +$71,485.48 | 1,162,308 | Indirect | |
| Jan 28, 2022 | Common Stock | PPurchaseAcquired | +17,119 | $50.56F9 | +$865,459.6 | 14,325,145 | Indirect | |
| Jan 28, 2022 | Common Stock | PPurchaseAcquired | +953 | $51.61F10 | +$49,187.76 | 1,163,261 | Indirect | |
| Jan 28, 2022 | Common Stock | PPurchaseAcquired | +11,526 | $51.61F10 | +$594,898.35 | 14,336,671 | Indirect | |
| Jan 31, 2022 | Common Stock | PPurchaseAcquired | +2,307 | $57.22F11 | +$132,007.69 | 1,165,568 | Indirect | |
| Jan 31, 2022 | Common Stock | PPurchaseAcquired | +27,841 | $57.22F11 | +$1,593,075.94 | 14,364,512 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares of common stock ("Common Stock") of Kodiak Sciences Inc. (the "Issuer") were traded by Baker Brothers Life Sciences, L.P. ("Life Sciences") in multiple transactions at prices ranging from $51.74 to $52.74, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were traded by Life Sciences in multiple transactions at prices ranging from $51.18 to $51.74, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported in Column 4 is a weighted average price. These shares were traded by the Funds in multiple transactions at prices ranging from $51.48 to $51.83, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
Referenced by the price of 2 transactions in Table I.
- F8
The price reported in Column 4 is a weighted average price. These shares were traded by the Funds in multiple transactions at prices ranging from $49.47 to $49.85, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
Referenced by the price of 2 transactions in Table I.
- F9
The price reported in Column 4 is a weighted average price. These shares were traded by the Funds in multiple transactions at prices ranging from $50.06 to $50.99, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
Referenced by the price of 2 transactions in Table I.
- F10
The price reported in Column 4 is a weighted average price. These shares were traded by the Funds in multiple transactions at prices ranging from $51.19 to $52.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
Referenced by the price of 2 transactions in Table I.
- F11
The price reported in Column 4 is a weighted average price. These shares were traded by the Funds in multiple transactions at prices ranging from $57.11 to $57.47, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
Referenced by the price of 2 transactions in Table I.
Remarks
Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC, the sole general partner of Baker Bros. Advisors LP, is a director of Kodiak Sciences Inc. (the "Issuer"). By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons are deemed directors by deputization of the Issuer.